Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Logan Brooks

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Investigation|January 5, 2005
SDF-1 is both necessary and sufficient to promote proliferative retinopathyJason M Butler, Steven M Guthrie, Mehmet Koc, et al.
Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Ophthalmology|March 4, 2023
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year ResultsCarl Regillo, Brian Berger, Logan Brooks, et al.
Ophthalmology. Retina|August 18, 2024
Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial DevelopmentDavid A Eichenbaum, William R Freeman, Margaret A Chang, et al.
Clinical Pharmacology and Therapeutics|August 4, 2021
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy VolunteersMichael J Dolton, Aaron Chesterman, Anita Moein, et al.
Critical Care Medicine|December 15, 2022
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 TrialMichael Waters, James A McKinnell, Andre C Kalil, et al.
Annals of Clinical and Translational Neurology|January 11, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALSJonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, et al.
Scientific Reports|January 26, 2019
Collaborative efforts to forecast seasonal influenza in the United States, 2015-2016Craig J McGowan, Matthew Biggerstaff, Michael Johansson, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2021
An open repository of real-time COVID-19 indicatorsAlex Reinhart, Logan Brooks, Maria Jahja, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Investigation|January 5, 2005
SDF-1 is both necessary and sufficient to promote proliferative retinopathyJason M Butler, Steven M Guthrie, Mehmet Koc, et al.
Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Ophthalmology|March 4, 2023
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year ResultsCarl Regillo, Brian Berger, Logan Brooks, et al.
Ophthalmology. Retina|August 18, 2024
Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial DevelopmentDavid A Eichenbaum, William R Freeman, Margaret A Chang, et al.
Clinical Pharmacology and Therapeutics|August 4, 2021
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy VolunteersMichael J Dolton, Aaron Chesterman, Anita Moein, et al.
Critical Care Medicine|December 15, 2022
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 TrialMichael Waters, James A McKinnell, Andre C Kalil, et al.
Annals of Clinical and Translational Neurology|January 11, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALSJonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, et al.
Scientific Reports|January 26, 2019
Collaborative efforts to forecast seasonal influenza in the United States, 2015-2016Craig J McGowan, Matthew Biggerstaff, Michael Johansson, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2021
An open repository of real-time COVID-19 indicatorsAlex Reinhart, Logan Brooks, Maria Jahja, et al.
Pageof 4